Preview

Medical alphabet

Advanced search

Specificity of dermatological adverse events of BCR-ABL tyrosine kinase inhibitors and their effect on quality of life of patients with chronic myeloid leukemia

https://doi.org/10.33667/2078-5631-2020-6-72-76

Abstract

Introduction. BCR-ABL tyrosine kinase inhibitors are currently used to successfully treat chronic myeloid leukemia (CML). Drug therapy is carried out in a continuous daily mode throughout the patient’s life. Treatment with this group of drugs is associated with specific dermatological adverse events (dAE), which can lead to a change in the regimen of effective, vital therapy for CML patients.

Purpose. To study the characteristics of dermatological adverse events, the severity and influence on the quality of life of BCR-ABL tyrosine kinase inhibitors.

Patients and methods. The observational study included 93 patients. The clinical manifestations of dAE, their severity were evaluated, their photographs and pathomorphological studies of skin biopsy samples were performed, cases of dose reduction or drug withdrawal due to dAE were recorded. The quality of life of patients with dAE was determined based on the assessment of the dermatological index of quality of life.

Results. Imatinib therapy was accompanied by a maculopapular rash in 43.3 % of patients, nilotinib caused follicular keratosis in 12.9 % of patients. In 3.2 % of patients, dasatinib caused hyperpigmentation, in 2.2 % of patients lichenoid rashes of the II degree occurred during treatment with bosutinib. Ponatinib treatment was followed by dAE in 9.7 % of patients. All dAE have an impact on the quality of life of patients, but the maculopapular rash and dyskeratotic changes are most pronounced. In a pathomorphological study, these dAE have specific features corresponding to immuno-mediated dermatitis.

Conclusions. The most frequent and pronounced dAE that significantly affect the quality of life of patients with CML are a maculopapular rash and dyskeratotic skin changes: psoriasiform and lichenoid dermatitis. Clinical and pathomorphological characteristics of skin reactions make it possible in the future to determine effective methods of supportive therapy for dAE.

About the Authors

E. A. Shatokhina
Central State Medical Academy of the Administrative Department of the President of Russia; National Medical Research Centre for Hematology
Russian Federation

Moscow



A. G. Turkina
National Medical Research Centre for Hematology
Russian Federation

Moscow



E. Yu. Chelysheva
National Medical Research Centre for Hematology
Russian Federation

Moscow



O. A. Shukhov
National Medical Research Centre for Hematology
Russian Federation

Moscow



A. N. Petrova
National Medical Research Centre for Hematology
Russian Federation

Moscow



A. M. Kovrigina
National Medical Research Centre for Hematology
Russian Federation

Moscow



L. S. Kruglova
Central State Medical Academy of the Administrative Department of the President of Russia
Russian Federation

Moscow



E. V. Ranenko
Central State Medical Academy of the Administrative Department of the President of Russia
Russian Federation

Moscow



P. G. Nosikova
Central State Medical Academy of the Administrative Department of the President of Russia
Russian Federation

Moscow



References

1. Туркина А. Г., Лазарева О.В, Челышева Е. Ю., Шухов О. А., Куликовский А.А, Галайко М. В., Сендерова О. М., Пепеляева В. М., Мересий С. В., Лучинин А. С., Милютина Г. И., Гаврилова Л. В., Авдеева Л. Б., Дашеева Д. Б., Виноградова О. Ю., Куликов С. М. Результаты терапии больных хроническим миелолейкозом по данным российской части международного многоцентрового популяционного исследования EUTOS population- based Study (EUTOS-PBS). Гематология и трансфузиология. 2019; 64 (2): 106–121.

2. Chereda B., Melo J. V. Natural course and biology of CML. Ann Hematol. 2015; 94 (2): 107–121.

3. Hehlmann R., Hochhaus A., Baccarani M. Chronic myeloid leukaemia. The Lancet. 2007; 370 (9584): 342–50.

4. Bower H., Bjorkholm M., Dickman P. W., et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. Journal of Clinical Oncology. 2016;34: 2851–7.

5. Туркина А. Г., Новицкая Н. В., Голенков А. К. и др. Регистр больных хроническим миелолейкозом в Российской Федерации: от наблюдательного исследования к оценке эффективности терапии в клинической практике. Клиническая онкогематология. 2017; 10 (3): 390–401.

6. Steegmann J. L., Baccarani M., Breccia M. et al. European Leukemia Net recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016; 30 (8): 1648–71.

7. US Department of Health and Human Services et al. Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute. 2009; 4 (03).

8. Finlay AY, Khan GK. The Dermatology Life Quality Index: A simple practical measure for routine clinical use. British Journal of Dermatology, 1993; 129 (Suppl. 42): 27.


Review

For citations:


Shatokhina E.A., Turkina A.G., Chelysheva E.Yu., Shukhov O.A., Petrova A.N., Kovrigina A.M., Kruglova L.S., Ranenko E.V., Nosikova P.G. Specificity of dermatological adverse events of BCR-ABL tyrosine kinase inhibitors and their effect on quality of life of patients with chronic myeloid leukemia. Medical alphabet. 2020;(6):72-76. (In Russ.) https://doi.org/10.33667/2078-5631-2020-6-72-76

Views: 510


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)